Company Overview and News

2
Highly influential, low profile: Why Eddington prefers movers like the Murdochs

2018-10-17 watoday.com.au
One of the curious conundrums of Sir Rod Eddington is that he remains prominent in the affairs of some of the world’s larger and more interesting companies but maintains a profile in this country that is quite out of proportion to his achievements during his public life. He remains highly influential but the profile is low.
GJV RTPPF RIO RIO NWS NWSA RIO RTNTF CLPHF 0002 CLPHY

2
Highly influential, low profile: Why Eddington prefers movers like the Murdochs

2018-10-17 theage.com.au
One of the curious conundrums of Sir Rod Eddington is that he remains prominent in the affairs of some of the world’s larger and more interesting companies but maintains a profile in this country that is quite out of proportion to his achievements during his public life. He remains highly influential but the profile is low.
GJV RTPPF RIO RIO NWS NWSA RIO RTNTF CLPHF 0002 CLPHY

2
Highly influential, low profile: Why Eddington prefers movers like the Murdochs

2018-10-17 smh.com.au
One of the curious conundrums of Sir Rod Eddington is that he remains prominent in the affairs of some of the world’s larger and more interesting companies but maintains a profile in this country that is quite out of proportion to his achievements during his public life. He remains highly influential but the profile is low.
GJV RTPPF RIO RIO NWS NWSA RIO RTNTF CLPHF 0002 CLPHY

 
Hong Kong stocks suffer biggest weekly loss in eight months

2018-10-05 scmp
Hong Kong stocks suffered their biggest weekly loss in eight months after sliding for a fourth day on Friday.
LNVGF 0700 LNVGY CLPHF 0002 0992 AACAY AACAF CLPHY

 
Low uptake of sustainability measures among Hong Kong and Asian firms could turn investors away

2018-09-27 scmp
Asia is failing to attach importance to environmental, social and governance (ESG) measures, falling behind Europe and the United States, which could harm investor interest, say experts.
CLPHF 0002 CLPHY

4
The US$4.4b Hong Kong residential enclave that cost US$41,000

2018-08-28 malaymail
HONG KONG, Aug 28 — The Kadoorie family is proving that anything’s possible in Hong Kong’s property market.
0146 CKHUF CIG CLPHF CKHUY 0002 CIGI CLPHY

4
The US$4.4b Hong Kong residential enclave that cost US$41,000

2018-08-28 theedgemarkets
HONG KONG (Aug 29): The Kadoorie family is proving that anything’s possible in Hong Kong’s property market.
0146 CKHUF CIG CLPHF CKHUY 0002 CIGI CLPHY

 
CLP Holdings Ltd. ADR 2018 Q2 - Results - Earnings Call Slides

2018-08-06 seekingalpha
The following slide deck was published by CLP Holdings Ltd. ADR in conjunction with their 2018 Q2 earnings call.
CLPHF 0002 CLPHY

8
Utilities Pooling Cash for $130 Million Clean Technology Fund - Bloomberg

2018-07-11 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
DUKH BRDCF INNYY CHUEF AEP DUK CLPHF 0002 CLPHY

 
Hong Kong, mainland stocks edge lower as US tariffs loom closer

2018-07-04 scmp
Stocks in Hong Kong and mainland China fell on Wednesday, as the deadline for the White House to impose the first round of tariffs on Chinese goods draws closer.
HGKGF HGKGY CLPHF 0002 AACAY AACAF CLPHY

1
MRCB bags gold at 2018 Australasian Reporting Awards

2018-06-25 malaymail
KUALA LUMPUR, June 25 — Malaysian Resources Corporation Berhad (MRCB) has won the Gold Award at the 2018 Australasian Reporting Awards (ARA).
1651 WOPEF CLPHF WPL 0002 WOPEY CLPHY

12
Hong Kong stocks in worst weekly decline since March as Trump adds to risk-off sentiment by axing Korea summit

2018-05-27 scmp
Hong Kong stocks posted their worst weekly drop in two months on Friday, after US President Donald Trump called off a planned summit with North Korean leader Kim Jong-Un.
HNNWY CLPHF 0002 CLPXY SMSOF SMSEY 1910 CLPXF 0958 MS 0836 CLPHY

 
Hong Kong utility CLP vows to help businesses and residents adopt renewable power generation 

2018-05-05 scmp
Scheme launching on October 1 will allow businesses and homeowners to sell excess output from devices such as rooftop solar panels back to energy suppliers
CLPHF 0002 CLPHY

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...